Media Partnership - Time is Now: Advancing Alzheimer's Disease Diagnosis & Care
13-06-2025
Imagine a world where the memories of your loved ones fade away, and the burden of care falls heavily on families.
Alzheimer’s disease (AD), the leading cause of dementia, is a progressive neurodegenerative disease, that robs people of their memories, their independence, their relationships and ultimately their futures.¹ AD also places a significant burden on loved ones – around seven out of ten people with AD live at home and nearly three-quarters of their care is provided by family members and friends.² In fact, 50% of all dementia costs are due to informal care.³ The societal cost of dementia in Europe is estimated to increase to over €250 billion by 2030, the equivalent of the whole GDP of Finland¹, causing growing public health challenges.
Despite its prevalence and impact, AD remains widely underdiagnosed and undermanaged (4-5). On average, it can take almost three years following the initial onset of symptoms for individuals with AD to be diagnosed (4). As many as 75% of people living with dementia globally are never diagnosed at all (5).
At this event attendees will hear exclusive real-world insights into the social and systemic barriers that are blocking access to timely diagnosis and intervention in AD when they could make the greatest difference. A panel of experts will explore the impact that delaying the diagnosis of AD can have on patients and caregivers, along with the benefits that an early, accurate diagnosis of AD can offer.
With new developments in AD diagnostics and management on the horizon, this event will consider the importance of taking collective action now to future-proof health care infrastructures, reflecting on what practical steps are needed to drive positive changes. Join us at this event to discover more and hear about the vital role policymakers must play in improving access to AD diagnosis and care.
References:
1. EBC and EFPIA. RETHINKING Alzheimer’s disease: Detection and diagnosis. 2023. Available at: https:// www.braincouncil.eu/wp-content/uploads/2023/04/RETHINK-AlzheimerDisease-Report_DEF3_HD_rvb_03042023.pdf. Last accessed: May 2025.
2. A Martin, M Sabbagh (2010) Palliative Care for Advanced Alzheimer’s and Dementia. Available at: https:// books.google.co.uk/books?hl=en&lr=&id=Iu3lO9xMruMC&oi=fnd&pg=PR2&ots=LqkE8NQ8U2&sig=_1K6Ex0f-4ZqOvJu5EbYNVmE2ZE&redir_esc=y#v=onepage&q&f=false 4
3. Wimo A, et al. Alzheimers Dement. 2023 Jul;19(7):2865-2873.
4. Dubois B, et al. Alzheimers Res Ther. 2023;15(1):175
5. Alzheimer’s Disease International, (2024). Dementia Statistics. Available at: https://www. alzint.org/about/dementia-facts-figures/dementia-statistics/#:~:text=Diagnosis,and%20documented%20in%20primary%20care. Last accessed: May 2025.
6. Alzheimer's Disease International. World Alzheimer Report 2022. Available at: https:// www.alzint.org/u/World-Alzheimer-Report-2022.pdf. Last accessed: May 2025.
PP-LN-BE-0040
This Virtual Conference is organised by Eli Lilly with Euractiv as Media Partner.
Location
Online
Panellists
Catherine Reed, Senior Director, Values, Evidence and Outcomes, Eli Lilly and Company
Angela Bradshaw, Director for Research, Alzheimer Europe
Dr. Jort Vijverberg, Alzheimer Center Amsterdam and Neuroscience Amsterdam
Moderator
Jennifer Baker
Euractiv
Schedule
13.00-13.05 Welcome, introductions and opening remarks
13.05-13.15 Presentation of new real-world data regarding current barriers to timely diagnosis of Alzheimer’s disease (AD)
13.15-13.40 Reflective group discussion on data findings, to consider:
• Impacts of delayed diagnosis on people with AD
• How data findings reflect speakers’ own experiences
• Why we must improve access to early diagnosis now
• Potential solutions to speed up diagnostic pathways
13.40-13.55 Q&A
13.55-14.00 Closing remarks
Contact
Juliette Burton
juliette.burton@euractiv.com